BNP Paribas Upgrades Koninklijke Philips (NYSE:PHG) to Outperform

Koninklijke Philips (NYSE:PHG - Get Free Report) was upgraded by stock analysts at BNP Paribas from a "neutral" rating to an "outperform" rating in a report issued on Tuesday, Marketbeat Ratings reports.

Other equities analysts also recently issued research reports about the stock. UBS Group upgraded shares of Koninklijke Philips from a "neutral" rating to a "buy" rating in a report on Thursday, February 20th. StockNews.com raised shares of Koninklijke Philips from a "hold" rating to a "buy" rating in a report on Thursday, February 20th. Finally, Jefferies Financial Group upgraded shares of Koninklijke Philips from an "underperform" rating to a "hold" rating in a research report on Tuesday, October 29th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy".

Koninklijke Philips Stock Performance

PHG traded up $0.01 during trading on Tuesday, reaching $26.04. The company's stock had a trading volume of 715,615 shares, compared to its average volume of 805,398. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.74 and a current ratio of 1.23. The company's fifty day moving average price is $26.35 and its 200-day moving average price is $28.07. Koninklijke Philips has a 52-week low of $19.75 and a 52-week high of $32.91. The company has a market capitalization of $24.47 billion, a price-to-earnings ratio of -30.99, a price-to-earnings-growth ratio of 0.82 and a beta of 0.77.

Koninklijke Philips (NYSE:PHG - Get Free Report) last posted its quarterly earnings results on Wednesday, February 19th. The technology company reported $0.54 EPS for the quarter, missing the consensus estimate of $0.55 by ($0.01). Koninklijke Philips had a negative net margin of 3.88% and a positive return on equity of 10.85%. The business had revenue of $5.38 billion during the quarter, compared to analyst estimates of $5.10 billion. On average, equities analysts forecast that Koninklijke Philips will post 1.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Koninklijke Philips

Large investors have recently added to or reduced their stakes in the business. Colonial Trust Co SC grew its position in shares of Koninklijke Philips by 724.0% in the fourth quarter. Colonial Trust Co SC now owns 1,409 shares of the technology company's stock valued at $36,000 after purchasing an additional 1,238 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Koninklijke Philips in the 3rd quarter valued at approximately $54,000. Farther Finance Advisors LLC grew its holdings in Koninklijke Philips by 37.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,150 shares of the technology company's stock valued at $54,000 after buying an additional 582 shares during the last quarter. Whipplewood Advisors LLC purchased a new position in Koninklijke Philips during the fourth quarter worth $55,000. Finally, Millstone Evans Group LLC acquired a new position in shares of Koninklijke Philips in the fourth quarter worth $60,000. 13.67% of the stock is owned by institutional investors and hedge funds.

Koninklijke Philips Company Profile

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.